StockWatch
·
KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD · QQ2 FY-2027 · THE CALL

40% revenue growth, margin headwind from ramp-ups and insurance delays

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsKIMSKrishna Institute of Medical Sciences Ltd11 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

No quantified FY27 guidance. Q1 margin (20.1%) vs Q2 claim of stability (20.5%) masks compression in AP. Capex plan stated (₹1,100 Cr / 18 mo) but execution timeline vague.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong 40% revenue growth driven by unit ramp-ups and volume expansion, but PAT growth muted at 3.6% due to margin compression (doubtful debt ₹7.5 Cr, fixed costs in new units, insurance delays blocking patient flow in Thane/Mahadevapura). Management expects stabilization in 3–4 quarters, but execution risk is real: six acquisitions/O&M deals in parallel, Sarvottam at 53–67x EBITDA, and regulatory uncertainty in Kerala.

₹1344.4 Cr

Revenue · +39.9% YoY

₹74.6 Cr

Reported PAT · +3.6% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Consolidated revenue ₹1,344 Cr, +39.9% YoY, +14% QoQ

MET

Delivered consolidated revenue ₹1,344.4 Cr matches guidance

EBITDA margin 20.5% in Q2 vs 20.1% in Q1, stable

OVERSTATED

Margin compression in AP and ramp-up units; doubtful debt INR7.5 Cr dragging consolidated margins

Kondapur revenue grew 70% in 3 months since opening

MET

Kondapur ramp documented; but margins fell due to high fixed costs and new programs (Vizag, Anantapur)

Q2 is bottom quarter for losses in new units; margins return to 30% in 3–4 quarters

OVERSTATED

Management assertion, not yet proven; similar claims made for Thane (insurance blocks), Mahadevapura (14-month payback for doctors)

PAT ₹76 Cr standalone YoY growth +8.5% (reported EPS ₹1.8, +8.5% YoY)

OVERSTATED

Standalone PAT growth only 5.5% (from ₹72 Cr in Q2 FY26 to ₹76 Cr); consolidated PAT ₹74.6 Cr, +3.6% YoY — muted

Earnings quality

What changed since the last call

Deltas vs. the prior call

Doubtful debt provision materialized in Q2

Downgrade

Not mentioned in Q1 call; INR7.5 Cr in Q2 due to AP government payment delays. Q3 recovery assumed but unproven.

Kondapur margins below expectation despite 70% ramp

Downgrade

Revenue grew 70%, but EBITDA margin fell in Andhra cluster to ~22% vs 24–25% prior. Fixed costs and new programs (Vizag, Anantapur) cited; recovery to 30% pushed to 3–4 quarters (vs prior 'next quarter' tone).

Insurance empanelment delays extended

Downgrade

Thane still not done; Mahadevapura down to 2–3 insurers. Management said 'ongoing', no clear end date. Prior call suggested near-term resolution.

Sarvottam acquisition at higher-than-typical entry multiple

New

₹80 Cr for 51% stake (₹157 Cr implied valuation for ₹1.2–1.5 Cr EBITDA = 105–131x). Not disclosed in Q1; new portfolio risk.

Capex plan clarified at ₹1,100 Cr over 18 months

Maintained

3 projects (Secunderabad, Rajahmund, Kondapur). Management reiterated no new hospital commissioning until stabilization (FY28+), aligning with prior guidance.

The Q&A

Analysts pressed hard on margin trajectory (Karan Vora, Damayanti Kerai), insurance delays (Rahul Jeewani), Kondapur occupancy (Yuvraj Sehrawat), and acquisition multiples (Simran Thakkar). Management mostly held ground but conceded margins are bottom in Q2, doubtful debt is a headwind, and insurance is 'ongoing'. On Sarvottam multiple, MD defended confidence in ramp but lacked concrete proof.

The exchanges that mattered

Anti-cancer drug margin impact — Shubh Kalra, Asit C. Mehra

Dodged

Final details yet to be disclosed (November 9th). Oncology not a big part of revenue; impact may not be significant. Management evaluating mitigation (package rate revisions).

Kondapur ramp & margins — Karan Vora, Goldman Sachs

Answered

Q1 Kondapur ₹623 Cr → Q2 ₹700 Cr. Revenue grew 70% in 3 months. But EBITDA margin dipped due to fixed costs, new programs (Vizag, Anantapur). Expected to normalize over 3–4 quarters to 30%.

AP cluster margins — Karan Vora, Goldman Sachs

Answered

Two new programs started (Vizag, Anantapur); fixed costs higher. Over 2–3 quarters should normalize. PBDT (doubtful debt from gov business) ₹8 Cr hit in Q2, reversal expected Q3 onwards.

Kondapur occupancy & beds — Rahul Jeewani, IIFL

Answered

500 beds commissioned, 70% occupancy. Remaining beds (old hospital) under review; will commission next year or next few quarters. Total potential ₹1,200 Cr revenue (5-year target).

Insurance empanelment status — Rahul Jeewani, IIFL

Partial

Thane still in struggle. Mahadevapura down to 2–3 insurance companies. Negotiations ongoing; no fixed timeline. Expected to progress towards end of year.

Electronic City breakeven — Rahul Jeewani, IIFL

Answered

Broke even in September 2026. EBITDA positive expected Q3. Q4 safer assumption given buffer for unforeseen.

Transplant market size & economics — Damayanti Kerai, HSBC

Partial

Kidney transplants in most units, liver/heart/lung in 5–8 units. Don't track EBITDA by therapy, but high realization and high cost. Net positive contribution.

Margin recovery timeline — Damayanti Kerai, HSBC

Answered

Except Electronic City, all EBITDA positive. Electronic City Q4 likely. Q2 is bottom; trajectory upward unless new hospital commissioned.

Secunderabad capacity & ramp — Karan Vora, Goldman Sachs

Answered

250 beds non-consensus (dialysis machines). Renovations on old hospital 250 beds. Onco expansion underway. Sports medicine program launched. Next phase adds 250 more.

Bangalore cluster operationalization — Yuvraj Sehrawat, ChrysCaptial

Answered

Thane, Bengaluru, Electronic City first new units; 70% occupancy target in 4–6 years. Some therapies need standalone presence (not multi-campus). Gradual ramp expected.

Rental cost escalation at Kondapur — Anshul Agrawal, Emkay

Answered

Kondapur rents only from June (3 months impact vs 1 month Q1). ₹5.5 Cr per month rental. Established; no further escalation. Merger of rental partner being evaluated.

Call option accounting transparency — Anshul Agrawal, Emkay

Answered

Call option fair value ₹13.2 Cr in Q2, accounted as extraordinary item below EBITDA. Corporate costs not assigned to call option revenue.

Capex breakup and future guidance — Simran Thakkar, Beas Capital

Answered

H1: INR275 Cr other assets, INR300 Cr Kondapur. Next 18 mo: ₹1,100 Cr on Secunderabad, Rajahmund, Kondapur. No new hospital till stabilization.

Long-term debt and utilization — Simran Thakkar, Beas Capital

Answered

QIP money marked for general purposes (loss funding, minority acquisitions). Long-term debt for capex. 25% of QIP allocated to general purposes.

Sarvottam acquisition valuation — Simran Thakkar, Beas Capital

Partial

Monthly revenue INR8–10 Cr, EBITDA INR1.2–1.5 Cr. Confident can ramp to INR7–8 Cr/month. Remaining 49% with existing doctor, option to buy at fixed multiples, no immediate plan.

Net debt and leverage — Rahul Jeewani, IIFL

Answered

Net debt ₹2,150 Cr. Net debt/EBITDA ~1.9x. Merger of rental partner may bring ₹400 Cr debt, loss only GST (18% saving).

Future expansion markets — Rahul Jeewani, IIFL

Answered

Secunderabad, Kondapur core markets. Rajahmund, Ongole in next 4–5 months. 400–500 beds addition over 24 months. Then stabilize and prepare for FY28+ expansion (Chennai, Kerala, etc.).

Kerala regulatory risk — Rahul Jeewani, IIFL

Dodged

Uncertain. Many governments considering transparency. KIMS yet to figure out method or impact. No visibility on regulation or outcome.

Guidance

Forward guidance and management's confidence

Kondapur ₹1,200 Cr revenue potential (5-year target)

Medium

Current ramp-up on track; 70% growth in 3 months. Assumes 500-bed + expansion to 1,250 beds. Long-term directional, not near-term quantified.

Stable growth across units; new-unit ramp expected to stabilize by end FY27

Medium

Management expects margin recovery post-stabilization (Q3–Q4 FY27 onwards). Capex-heavy phase for next 18 months; growth moderated post capex cycle.

Telangana 30% EBITDA margin at scale (Kondapur, Secunderabad)

Medium

Aspirational. Kondapur currently dipped to ~20%; management expects 3–4 quarters to return to 30%. Unproven timeline.

AP 25% margin by FY27 end; Kerala 20–22% at maturity

Low

AP currently ~22%, dragged by new programs, insurance delays. Kerala data limited (only 1 O&M hospital). Regulatory uncertainty (pricing control) adds risk.

₹1,100 Cr capex over next 18 months (Secunderabad, Rajahmund, Kondapur)

High

H1 capex ₹650 Cr (₹300 Kondapur, ₹275 other). Debt-funded; long-term borrowing ₹3,600 Cr raised. Capital-heavy growth phase through FY27.

No new hospital commissioning until stabilization (FY28+); greenfield/M&A resume post-FY27

High

Management reiterated 'stabilization first' strategy. Chennai 300-bed target FY29 onwards. Shift from capex-led to M&A-led post-FY27.

Risks the call surfaced

Ranked by how much they should concern a holder

Insurance empanelment

High

Thane & Mahadevapura unable to tie up major insurers (Thane none, Maha 2–3 only). Government business high but slow payers (PBDT ₹7.5 Cr Q2). Revenue and margins pressured until resolved.

Margin recovery timeline

High

New-unit ramps (Kondapur, Secunderabad, Bengaluru, Thane, Mahadevapura) all sub-scale with high fixed costs. Management claims Q2 is bottom and margins return to 30% in 3–4 quarters, but AP currently ~22%, Kondapur dipped despite 70% growth. If insurance delays persist or new programs drag longer, margin recovery pushed beyond FY27 end.

Acquisition valuation

High

Sarvottam Healthcare: ₹80 Cr for 51% stake (₹157 Cr implied EV for ₹1.2–1.5 Cr EBITDA = 105–131x EBITDA). Management confident in ramp to ₹7–8 Cr/month, but execution unproven. 6 concurrent acquisitions (Sarvottam, Arete, Westfort, Abhinav Sangli, Kompally, Sikhara) + 28 existing hospitals create integration bandwidth risk.

Capex intensity and leverage

Medium

₹1,100 Cr capex over 18 months; ₹3,600 Cr long-term debt raised. Net debt ₹2,150 Cr (~1.9x EBITDA). If new hospitals ramp slower (insurance delays, market saturation, physician availability), leverage will remain elevated, limiting financial flexibility.

Regulatory and pricing pressure

Medium

Anti-cancer drug trade margin regulation (announcement Nov 9th). Kerala government considering private hospital pricing control. Management stated no visibility on impact but acknowledged risk. Could reset oncology and other high-margin segments.

Management

Score 7/10. Clear on financials (revenue, EBITDA, capex); transparent on challenges (insurance delays, PBDT, margin compression in ramps). Deferred anti-cancer drug impact (Nov 9th), unclear on Kerala regulation. Confident tone may overstate execution readiness given 6 concurrent acquisitions. Track record mixed. Sai Veera Hospital (Anantapur) doubled capacity on time. Kondapur ramp-up documented (70% growth in 3 months). But Electronic City took longer to breakeven; Thane and Mahadevapura still struggling on insurance after 12–15 months. Doubtful debt provision not previously highlighted.

What to watch next
  • 1 · Nov 09, 2026

    Anti-cancer drug trade margin cap impact to be disclosed

  • 2 · Q3 FY27

    Electronic City EBITDA breakeven; Thane insurance empanelment complete

  • 3 · Q3/Q4 FY27

    Doubtful debt reversal expected; Insurance settlement completion

Management expects stabilization in 3–4 quarters, but execution risk is real: six acquisitions/O&M deals in parallel, Sarvottam at 53–67x EBITDA, and regulatory uncertainty in Kerala.

Informational and educational content only. Not investment advice.